Latest news
Ocular Therapeutix's NDA Plans for Axpaxli in Wet AMD Remain on Track, RBC Says - marketscreener.commarketscreener.com · Tue, 04 Aug 2026 16:00:37 GMTOcular Therapeutix Earns Buy Rating on Reduced Regulatory Risk and Strong Axpaxli NDA Visibility - TipRanksTipRanks · Tue, 04 Aug 2026 05:52:32 GMTOcular Therapeutix reports Q2 2026: $13.5M revenue, $78.8M net loss, $598.6M cash - TradingViewTradingView · Mon, 03 Aug 2026 11:23:01 GMTOCUL: Strong Phase 3 data for AXPAXLI drives NDA plans, but losses widen as R&D and launch costs rise - TradingViewTradingView · Mon, 03 Aug 2026 11:17:23 GMTOcular Therapeutix Reports Q2 2026 Results, Confirms Q4 2026 AXPAXLI NDA Submission Plan for Wet AMD - Quiver QuantitativeQuiver Quantitative · Mon, 03 Aug 2026 11:15:00 GMTOCUL: AXPAXLI NDA submission set for Q4 2026, with strong trial results and cash runway into 2028 - TradingViewTradingView · Mon, 03 Aug 2026 11:12:32 GMT